Cowen resumed coverage on Absci Corporation
$ABSI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Cowen resumed coverage of Absci Corporation with a rating of Market Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $9.00 | Buy | Needham |
| 10/2/2024 | $10.00 | Buy | Guggenheim |
| 7/3/2024 | $7.00 | Overweight | Morgan Stanley |
| 3/14/2024 | $13.00 | Sector Outperform | Scotiabank |
| 12/5/2023 | $3.00 | Overweight | KeyBanc Capital Markets |
| 5/4/2023 | $4.00 | Buy | H.C. Wainwright |
| 8/12/2022 | Overweight → Underweight | JP Morgan | |
| 7/18/2022 | $8.00 | Buy | Truist |
Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00
Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00
Morgan Stanley initiated coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00